ClinicalTrials.gg
RecruitingNCT06687876MEMENTOUpdated Jul 10, 2025

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

A Phase 2 interventional study of Metformin in Oesophageal Adenocarcinoma and Tumor Microenvironment, sponsored by Amsterdam UMC, location VUmc. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Amsterdam UMC, location VUmc · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands — 11 open to participants now, 16 under way, 3 of them phase 3. Adenocarcinoma Of Esophagus · Netherlands.

Planned enrollment
17th of 17
14 · median 195
Started
2025
with 3 others
Phase 2
7 of 25
4 open now
Primary completion
2026-12
later than 7 of 15 live
Registered
22nd of 25
by date
Lead sponsor
1 of 25
Amsterdam UMC, location VUmc

Among the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands, this one is the 17th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 22nd registered.

Adenocarcinoma Of Esophagus

353 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

11 of the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.

Read the detailed description

Worldwide oesophageal adenocarcinoma (OAC) is one of the most deadly cancers. Even in case of non-metastatic disease, when patients are treated with neoadjuvant chemoradiotherapy (nCRT) and a surgical resection, around 50% of patients suffer from recurrent disease which is associated with a poor prognosis. While 23% of OACs have a complete histopathological response after nCRT, 18-35% lack any effect of nCRT. Previously, we have identified that a complete pathological response to nCRT is associated with an active tumour immune microenvironment (TIME) characterized by high intratumoral T cell levels and a higher CD3:CD163 ratio.

To improve response to nCRT we need to identify and target the mechanisms OACs use to suppress the TIME. Using spatial transcriptomics to identify differences between OACs with a T cell-dominant and a T cell-excluded microenvironment, we identified fatty acid oxidation (FAO) as central feature of T cell low OACs (unpublished data). This is an interesting observation as lipid metabolism is strongly associated with an immunosuppressive microenvironment. Metabolic re-programming by drugs such as metformin has shown to be a promising strategy to reactivate the anti-tumour immune response in other cancer types.

Over the past decade, metformin has been associated with a beneficial effect in cancer treatment as it has shown to decrease the risk of various cancer types in diabetic patients. More recent, metformin treatment has shown to increase the number of CD8+ tumour infiltrating lymphocytes by preventing apoptosis of these lymphocytes in cancers such as oesophageal squamous cell carcinomas. In addition, metformin can reduce M2-like macrophage polarization due to changes in cytokine expression in cancer cells and thereby stimulate a more pro-inflammatory TIME. In this study we want to investigate the effect of metformin on the TIME in patients with OACs using pre- and post-treatment tumour biopsies prior to nCRT.

03

Conditions studied

  • Oesophageal Adenocarcinoma
  • Tumor Microenvironment

Keywords

  • metabolic intervention
  • adenocarcinoma
  • oesophageal cancer
  • metformin
  • tumor microenvironment
  • neoadjuvant chemoradiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgical resectable (\<T4b, N0 or N+, M0), and proven adenocarcinoma of the oesophagus or gastro-oesophageal junction planning to undergo chemoradiotherapy.
  • Adult patients (age ≥ 18 years).
  • performance status 0 or 1 (cf. Appendix A).
  • Adequate hematological, renal and hepatic functions defined as:

    • ≥ 1.5 x 10\^9/L
    • ≥ 100 x 10\^9/L
    • ≥ 5.6 mmol
    • Total ≤ 1.5 x upper normal limit
    • (Cockroft) > 30 ml/min
  • Patients must be willing to undergo two endoscopies for purposes.
  • Written, voluntary .
  • Patients must be accessible to follow up and management in the treatment center.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with diabetes mellitus type 1 or 2 receiving anti-diabetic drugs.
  • Patients prescribed metformin or another anti-diabetic drug for any reason.
  • Patients allergic or intolerant to metformin.
  • Excessive alcohol consumption.
  • Use of OCT1/OCT2 inhibitors (e.g. verapamil, cimetidine, dolutegravir, isavuonazol, trimethoprim, vandetanib, crizotinib and Olaparib).
  • Use of OCT1/OCT2 inducers (e.g. rifampicine).
  • Use of medication (, cyclosporine, tacrolimus, sirolimus, everolimus, cyclophosphamide).
  • Previous systemic therapy or radiotherapy on the oesophagus.
  • Severe renal impairment ( ≤ 30 ml/min).
  • Past (within 5 years) or current history of other than entry diagnosis interfering with prognosis of oesophageal cancer.
  • Previous systemic therapy for other forms of cancer within the last six months.
  • Patients with prior allogeneic stem cell or solid organ transplantation
  • Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
  • cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery.
  • Pulmonary fibrosis, active, non-infectious pneumonitis and/or severely impaired lung function precluding major surgery and/or radiation.
  • Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine.
  • Dementia or altered mental status that would prohibit the understanding and giving of .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Metformin

    1000 mg (twice a day 500 mg) metformin orally will be administered during a 2-week period. This is followed by the standard of care, which is neoadjuvant chemoradiotherapy, involving paclitaxel (50 mg/m2), carboplatin (AUC=2), and radiotherapy (23 x 1.8 Gy over five weeks) followed by surgical resection.

    Drug: Metformin

Interventions

  • Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.

    Also known as: Glucient

06

What researchers measure

Primary outcomes

  1. activation of the tumour immune microenvironment after two week metformin treatment.

    Activation of the tumor immune microenvironment measured by M2 to M1 polarization, CD8 intratumoral T cell infiltration and an increase of CD3 to CD163 ratio when comparing tumor biopsies from before and after treatment.

    Time frame: at enrollment and at end of metformin treatment at 2 weeks.

Secondary outcomes

  1. Tolerability and toxicity of metformin

    Adverse events based on Common Toxicity Criteria for Adverse Events

    Time frame: From starting treatment to end of treatment at 7 weeks.

  2. Metabolic change of cancer cells with SCENITH analysis.

    To determine whether SCENITH can be used to assay the change in metabolic state.

    Time frame: at enrollment and at end of metformin treatment at 2 weeks

  3. Pathological response

    According to the Mandard criteria.

    Time frame: After surgery, approximately 16 weeks after enrollment.

  4. Progression-free survival (PFS).

    Assess the PFS of patients within the study

    Time frame: 60 months

  5. Overall survival (OS)

    Determine overall survival of patients within the study

    Time frame: 60 months

Other outcomes

  1. Can metformin induce a metabolic switch in macrophages, T cells and cancer cells.

    Using single cell RNA sequencing or SCENITH analysis.

    Time frame: 20 months

  2. Change in subgroups in peripheral blood mononuclear cells (PMBCs) after metformin treatment.

    Are the changes to the tumour immune microenvironment also detected in subgroups of peripheral blood mononuclear cells (PBMCs) taken at the same time points.

    Time frame: 20 months

  3. Establish immune cell co-cultures with primary tumour cells and investigate the cell interactions and anti-tumour responses in presence of metformin.

    Establish autologous immune cell co-cultures with primary tumor cells to investigate immune cell-tumor cell interactions and anti-tumour responses in the presence of metformin.

    Time frame: 20 months

  4. Cytokine release profile measured in serum before and after metformin treatment.

    Determine changes in cytokine expression in serum before and after metformin treatment.

    Time frame: 20 months

  5. changes in ctDNA in patient plasma before and after metformin treatment.

    To evaluate changes in the presence of circulating tumour DNA (ctDNA) extracted from patient plasma and their correlation with pathological response and survival.

    Time frame: 20 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It is undecided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 51 non-industry phase 2 interventional studies under Adenocarcinoma Of Esophagus, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 21 months is below that.

Counting every sponsor, half of 60 studies reached it within 55 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 14, 2024
StartActual
Mar 9, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2030
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06687876
Collaborators
Cancer Center Amsterdam Research Foundation
Responsible party
Sarah Derks (MD PhD, Amsterdam UMC, location VUmc) — Principal investigator
First posted
Nov 14, 2024
Start date
Mar 9, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jul 10, 2025

Study contacts

Kayla Brugman, Master of Medicine
Contact
c.brugman@amsterdamumc.nl
+3120 44 45869
Sarah Derks, MD PhD
principal investigator · Amsterdam UMC, location VUmc
Hanneke W.M. van Laarhoven, MD, PhD
principal investigator · Amsterdam UMC, location VUmc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion